

WEST[Help](#)[Logout](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Generate Collection](#)**Search Results - Record(s) 1 through 12 of 12 returned.**☐ 1. Document ID: AU 9871999 A, WO 9855036 A1

Entry 1 of 12

File: DWPI

Dec 21, 1998

DERWENT-ACC-NO: 1999-045446

DERWENT-WEEK: 199919

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Removal of highly vascularised tissue - includes use of wire made as snare to act as 1 electrode and passage of current through snare tightened around tissue to be removed

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 2. Document ID: RU 2112134 C1

Entry 2 of 12

File: DWPI

May 27, 1998

DERWENT-ACC-NO: 1998-608254

DERWENT-WEEK: 199851

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Hydrate and paraffin bottleneck break up device - has working strands of cable connected in pairs to three-phase current source and uses free strand for connection of additional devices in heater

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 3. Document ID: CN 1227607 A, WO 9806248 A2, AU 9739728 A, EP 918797 A2

Entry 3 of 12

File: DWPI

Sep 1, 1999

DERWENT-ACC-NO: 1998-159172

DERWENT-WEEK: 199953

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Humanised immunoglobulin reactive with alpha-4-beta-7 integrin - used for treating inflammatory disease, pancreatitis, diabetes, asthma, graft versus host disease and sarcoidosis

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

☐ 4. Document ID: RU 2087978 C1

Entry 4 of 12

File: DWPI

Aug 20, 1997

DERWENT-ACC-NO: 1998-177833

DERWENT-WEEK: 199816

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Temperature sensor-relay - has sensitive element to bend during change of temperature and activate sensor and uses force element to return sensitive element after fall of temperature

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 5. Document ID: US 5912565 A, JP 09190691 A, TW 333649 A, KR 97049299 A

Entry 5 of 12

File: DWPI

Jun 15, 1999

DERWENT-ACC-NO: 1997-422253

DERWENT-WEEK: 199930

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Motion control circuit of power supply appts used in memory - has latch which is reset after predetermined time by signal from delay sensing circuit, such that power supply is operated based on motion control signal

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 6. Document ID: RU 2073288 C1

Entry 6 of 12

File: DWPI

Feb 10, 1997

DERWENT-ACC-NO: 1997-401208

DERWENT-WEEK: 199737

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Fuel element of electrochemical generator - has micro-spaces in form of casing surrounded by fuel and uses molecular catalyst and electrode ceramic layers to form outer layer of micro-spaces

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 7. Document ID: WO 9306713 A1, JP 07503126 W, EP 666921 A1, EP 666921 A4, US 5684239 A

Entry 7 of 12

File: DWPI

Apr 15, 1993

DERWENT-ACC-NO: 1993-134024

DERWENT-WEEK: 199750

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Systems for expression of dicot wound inducible promoter - for use in transformed monocots for expression of natural insecticide in direct response to attack

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 8. Document ID: JP 02049583 A

Entry 8 of 12

File: DWPI

Feb 19, 1990

DERWENT-ACC-NO: 1990-096515

DERWENT-WEEK: 199013

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: High yield prepn. of beta-D-1,2-glucanase - comprises using novel acremonium Sp-15 DK 2015 FERM-9-9019

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 9. Document ID: BE 799854 A, CA 985509 A, FR 2186434 A, GB 1384346 A, JP 49042523 A, JP 79009573 B, US 3887679 A, ZA 7303631 A

Entry 9 of 12

File: DWPI

DERWENT-ACC-NO: 1973-80747U

DERWENT-WEEK: 197352

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Separating copper and cobalt - by extraction from soln contg hydrochloric acid

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 10. Document ID: BE 791923 A, DE 2359025 B

Entry 10 of 12

File: DWPI

DERWENT-ACC-NO: 1973-39625U

DERWENT-WEEK: 197328

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Butt welding strip metal - appts provides quick welds for strip in tube making appts

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 11. Document ID: NL 7011542 A, BE 754593 A, DE 2039362 A, FR 2056727 A

Entry 11 of 12

File: DWPI

DERWENT-ACC-NO: 1971-13047S

DERWENT-WEEK: 197107

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Dehydrated food product from soya-beans

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

- ☐ 12. Document ID: DE 1644456 A

Entry 12 of 12

File: DWPI

Apr 8, 1971

DERWENT-ACC-NO: 1984-295085

DERWENT-WEEK: 198448

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: New anthraquinone dye for synthetic fibres - prepd. by adding 1-amino-4-pa ra-anisidine- anthraquinone to double bond of gamma-chloropropylene glycol acrylate

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Image
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------

Generate Collection

Term	Documents
ACT.DWPI.	100592
ACTS.DWPI.	101657
"1".DWPI.	17085972
1S.DWPI.	1129
(ACT ADJ1 "1").DWPI.	12

Display 50 Documents

including document number

12

Display Format:

TI

Change Format

Main Menu

Search Form

Posting Counts

Show S Numbers

Edit S Numbers

Help

Logout

begin 652,653,654

< 03apr00 12:13:07 User208760 Session D1506.2
\$0.00 0.049 DialUnits File410
\$0.00 Estimated cost File410
\$0.01 TYMNET
\$0.01 Estimated cost this search
\$0.42 Estimated total session cost 0.153 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 652:US Patents Fulltext 1971-1979
(c) format only 2000 The Dialog Corp.
*File 652: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.
File 653:US Patents Fulltext 1980-1989
(c) format only 2000 The Dialog Corp.
*File 653: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.
File 654:US Pat.Full. 1990-2000/Mar 28
(c) format only 2000 The Dialog Corp.
*File 654: Reassignment data current through 12/06/1999 recordings.
Due to recent processing problems, the SORT command is not working.

Set	Items	Description
---	-----	-----
? s	(act(w)1) (30n)	(antibod? or hybridoma?)
Processing		
Processing		
Processing		
Processing		
Processing		
Processing		
Processing		
	333978	ACT
	2955794	1
	41482	ANTIBOD?
	9208	HYBRIDOMA?
S1	9	(ACT(W)1) (30N) (ANTIBOD? OR HYBRIDOMA?)
? t	s1/3/all	

1/3/1 (Item 1 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03076195

Utility
4-SUBSTITUTED-4-PIPERIDINE CARBOXAMIDE DERIVATIVES

PATENT NO.: 6,020,347
ISSUED: February 01, 2000 (20000201)
INVENTOR(s): DeLaszlo, Stephen E., Rumson, NJ (New Jersey), US (United States of America)
Hagmann, William K., Westfield, NJ (New Jersey), US (United States of America)
ASSIGNEE(s): Merck & Co Inc, (A U.S. Company or Corporation), Rahway, NJ (New Jersey), US (United States of America)
[Assignee Code(s): 54136]
APPL. NO.: 9-191,902

CROSS REFERENCE TO RELATED APPLICATIONS

This application is based on, and claims priority from, U.S. provisional application Ser. No. 60-065,917 filed Nov. 17, 1997, which is hereby incorporated by reference in its entirety.

FULL TEXT: 1975 lines

1/3/2 (Item 2 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

03055098

Utility
COMPOSITION OF C-KIT LIGAND, GM-CSF, AND TNF- α . AND METHOD OF USE

PATENT NO.: 6,001,803
ISSUED: December 14, 1999 (19991214)
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)
Buck, Jochen, New York, NY (New York), US (United States of America)
Moore, Malcolm A. S., New York, NY (New York), US (United States of America)
Nocka, Karl, Harvard, MA (Massachusetts), US (United States of America)
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 1305]
APPL. NO.: 8-325,240
FILED: October 20, 1994 (19941020)
PRIORITY: PCT-US93-03640, WO (World Intellectual Property Org), April 16, 1993 (19930416)

This invention is a continuation-in-part application of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, the contents of which is incorporated by reference into the present application.

The invention described herein was made in the course of work under Grant No. R01-CA 32926 and ACS KV246D from the National Institute of Health and American Cancer Society, respectively. The United States Government has certain rights in this invention.

FULL TEXT: 3621 lines

1/3/3 (Item 3 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02983724

Utility
METHOD FOR INCREASING THE LEVEL OF STEM CELLS IN PERIPHERAL BLOOD

PATENT NO.: 5,935,565
ISSUED: August 10, 1999 (19990810)
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)
Buck, Jochen, New York, NY (New York), US (United States of America)
Moore, Malcolm A. S., New York, NY (New York), US (United States of America)

States of America)
Nocka, Karl Harvard, MA (Massachusetts), US (United States
of America)
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research, (A U.S. Company
or Corporation), New York, NY (New York), US (United States of
America)
[Assignee Code(s): 1305]
APPL. NO.: 8-478,414
FILED: June 07, 1995 (19950607)

This application is a continuation application U.S. Ser. No. 08-341,456,
filed Nov. 17, 1995, now U.S. Pat. No. 5,767,074, which is a continuation
of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, a
continuation-in-part of PCT International Application No. PCT-US91-06130,
filed Aug. 27, 1991, a continuation-in-part of U.S. Ser. No. 07-594,306,
filed Oct. 5, 1990, and a continuation-in-part of U.S. Ser. No. 07-573,483,
filed Aug. 27, 1990, now abandoned, the contents of which are hereby
incorporated by reference.

The invention described herein was made in the course of work under Grant
No. R01-CA 32926 and ACS MV246D from the National Institute of Health and
American Cancer Society, respectively. The United States Government has
certain rights in this invention.

FULL TEXT: 3406 lines

1/3/4 (Item 4 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02970121

Utility
METHODS OF INHIBITING CANCER BY USING SUPERFIBRONECTIN

PATENT NO.: 5,922,676
ISSUED: July 13, 1999 (19990713)
INVENTOR(s): Pasqualini, Renata, Solana Beach, CA (California), US (United
States of America)
Ruoslahti, Erkki, Rancho Santa Fe, CA (California), US (United
States of America)
ASSIGNEE(s): The Burnham Institute, (A U.S. Company or Corporation), La
Jolla, CA (California), US (United States of America)
[Assignee Code(s): 41683]
APPL. NO.: 8-717,169
FILED: September 20, 1996 (19960920)

This invention was funded in part by NIH Grant Nos. CA62042 and CA30199.
Accordingly, the United States government has certain rights in the
invention.

FULL TEXT: 1855 lines

1/3/5 (Item 5 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02966962

Utility
VACCINE FOR CLOSTRIDIUM BOTULINUM NEUROTOXIN

PATENT NO.: 5,919,665
ISSUED: July 06, 1999 (19990706)
INVENTOR(s): Williams, James A., Madison, WI (Wisconsin), US (United States
of America)

ASSIGNEE(s): Ophidian Pharmaceuticals, Inc , (A U.S. Company or Corporation), Madison, WI (Wisconsin), US (United States of America)
[Assignee Code(s): 30373]
APPL. NO.: 8-405,496
FILED: March 16, 1995 (19950316)

This application is a Continuation-in-Part of application Ser. No. 08-329,154 filed, Oct. 24, 1994, now abandoned, which is a Continuation-in-Part of application Ser. No. 08-161,907, filed on Dec. 2, 1993, now U.S. Pat. No. 5,601,823; which is a Continuation-in-Part of application Ser. No. 07-985,321, filed Dec. 4, 1992, which is a Continuation-in-Part of application Ser. No. 429,791, filed Oct. 31, 1989 now issued as U.S. Pat. No. 5,196,193 on Mar. 23, 1993.

FULL TEXT: 10143 lines

1/3/6 (Item 6 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02952447

Utility
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED MOLECULES FOR TREATMENT OF
INFLAMMATORY ARTHRITIS

PATENT NO.: 5,906,820
ISSUED: May 25, 1999 (19990525)
INVENTOR(s): Bacha, Patricia A., Hollis, NH (New Hampshire), US (United States of America)
ASSIGNEE(s): Seragen, Inc , (A U.S. Company or Corporation), Hopkinton, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 28198]
APPL. NO.: 8-851,408
FILED: May 05, 1997 (19970505)

This is a continuation of application Ser. No. 08-458,719 filed on Jun. 3, 1995 (now abandoned), which is a continuation of Ser. No. 08-116,806 filed on Sep. 3, 1993 (U.S. Pat. No. 5,614,488), which is a continuation of Ser. No. 08-005,871 filed on Jan. 15, 1993 (now abandoned), which is a continuation of Ser. No. 07-726,316 filed on Jul. 5, 1991, now abandoned.
FULL TEXT: 773 lines

1/3/7 (Item 7 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02799866

Utility
COMPOSITIONS OF SOLUBLE C-KIT LIGAND AND HEMATOPOIETIC FACTORS
[Comprises a soluble c-kit ligand protein and one or more hematopoietic factors selected from interleukins, granulocyte-macrophage-colony stimulating factor, granulocyte-colony stimulating factor or erythropoietin]

PATENT NO.: 5,767,074
ISSUED: June 16, 1998 (19980616)
INVENTOR(s): Besmer, Peter, New York, NY (New York), US (United States of America)
Buck, Jochen, New York, NY (New York), US (United States of America)
Moore, Malcolm A.S., New York, NY (New York), US (United States of America)
Nocka, Karl, Harvard, MA (Massachusetts), US (United States of America)

of America)
ASSIGNEE(s): Sloan-Kettering Institute for Cancer Research (A U.S. Company or Corporation), New York, NY (New York), US (United States of America)
[Assignee Code(s): 1305]
APPL. NO.: 8-341,456
FILED: November 17, 1994 (19941117)

This invention is a continuation of U.S. Ser. No. 07-873,962, filed Apr. 23, 1992, now abandoned, which is a continuation-in-part application of PCT-US91-06130, filed Aug. 27, 1991, which is a continuation-in-part of U.S. Ser. No. 594,306, filed Oct. 5, 1990, which in turn is a continuation-in-part of U.S. Ser. No. 573,483, filed Aug. 27, 1990, now abandoned, the contents of all three are hereby incorporated by reference into the present application.

The invention described herein was made in the course of work under Grant No. R01-CA 32926 and ACS MV246D from the National Institute of Health and American Cancer Society, respectively. The United States Government has certain rights in this invention.

FULL TEXT: 3356 lines

1/3/8 (Item 8 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02632081

Utility
EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED MOLECULES FOR TREATMENT OF
INFLAMMATORY ARTHRITIS
[Cytotoxic fragment of a peptide toxin]

PATENT NO.: 5,614,488
ISSUED: March 25, 1997 (19970325)
INVENTOR(s): Bacha, Patricia A., Hollis, NH (New Hampshire), US (United States of America)
ASSIGNEE(s): Seragen, Inc, (A U.S. Company or Corporation), Hopkinton, MA (Massachusetts), US (United States of America)
[Assignee Code(s): 28198]
APPL. NO.: 8-116,806
FILED: September 03, 1993 (19930903)

This is a continuation of application Ser. No. 08-005,871, filed Jan. 15, 1993, now abandoned; which is a continuation of 07-726,316, filed Jul. 5, 1991, now abandoned.

FULL TEXT: 759 lines

1/3/9 (Item 9 from file: 654)
DIALOG(R)File 654:US Pat.Full.
(c) format only 2000 The Dialog Corp. All rts. reserv.

02314811

Utility
TREATMENT OF ACCELERATED ATHEROSCLEROSIS WITH INTERLEUKIN-2 RECEPTOR
TARGETED MOLECULES
[Cytotoxins]

PATENT NO.: 5,326,559
ISSUED: July 05, 1994 (19940705)
INVENTOR(s): Miller, D. Douglas, 7295 Greenway Ave., University City, MO (Missouri), US (United States of America), 63130

APPL. NO.: [Assignee C (s): 68000]
7-701,219
FILED: May 16, 1991 (19910516)
FULL TEXT: 693 lines
? t sl/k/all

1/K/1 (Item 1 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
...stimulated with proinflammatory cytokines." Immunol. 89, 375 (1996)).

At present, there is a humanized monoclonal **antibody** (Antegren(r) Athena Neurosciences/Elan) against VLA-4 in clinical development for the treatment of "flares" associated with multiple sclerosis and a humanized monoclonal **antibody** (ACT-1 (r) LeukoSite) against alpha sub 4 beta sub 7 in clinical development for the treatment...

1/K/2 (Item 2 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... ZBI (Coulter Electronics, Hialeah, Fla.). All plasticware used was of tissue culture grade.

Cytokines and **Antibodies**. Purified rhIL-1 beta, sp act=1.32X10 sub 7 U/mg, (Syntex Laboratories, Inc., Palo Alto, Calif.) was used at 100...

1/K/3 (Item 3 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... ZBI (Coulter Electronics, Hialeah, Fla.). All plasticware used was of tissue culture grade.

Cytokines and **Antibodies**

Purified rhIL-1 beta, sp act=1.32X10 sub 7 U/mg, (Syntex Laboratories, Inc., Palo Alto, Calif.) was used at 100...

1/K/4 (Item 4 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... Sheppard (University of California, San Francisco), and the anti- alpha sub 4 beta sub 7 (Act-1) **antibody** was from Dr. Andrew Lazarovits (University of Western Ontario, Canada).

The migration assays of FIG...

1/K/5 (Item 5 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.

1/K/6 (Item 6 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... are three ways in which the EGF receptor targeted molecules useful in the invention can act: (1) the ...molecule can kill a cell by virtue of a cytotoxic domain; (2) the molecule (an **antibody**) can cause cell lysis by inducing complement fixation; or (3) the molecule can block binding...

1/K/7 (Item 7 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... ZBI (Coulter Electronics, Hialeah, Fla.). All plasticware used was of tissue culture grade.

Cytokines and **Antibodies**. Purified rhIL-1 beta, sp act
1.32X10 sup 7 mu /mg, (Syntex Laboratories, Inc.,: Palo Alto, Calif.)
was used at 100...

1/K/8 (Item 8 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... are three ways in which the EGF receptor targeted molecules useful in the invention can act: (1) the molecule can kill a cell by virtue of a cytotoxic domain; (2) the molecule (an **antibody**) can cause cell lysis by inducing complement fixation; or (3) the molecule can block binding...

1/K/9 (Item 9 from file: 654)
DIALOG(R)File 654:(c) format only 2000 The Dialog Corp. All rts. reserv.
... In general, there are three ways in which the molecules useful in the invention can act: (1) the molecule can kill a cell because the molecule has a cytotoxic domain; (2) the molecule (an **antibody**) can cause cell lysis by inducing complement fixation; and (3) the molecule can block binding...

begin 5,73,155,399

03apr00 12:19:03 User208760 Session D1506.3
\$3.56 0.604 DialUnits File652
\$3.56 Estimated cost File652
\$5.88 0.996 DialUnits File653
\$5.88 Estimated cost File653
\$15.53 2.633 DialUnits File654
\$5.85 9 Type(s) in Format 3
\$0.00 9 Type(s) in Format 95 (KWIC)
\$5.85 18 Types
\$21.38 Estimated cost File654
OneSearch, 3 files, 4.233 DialUnits FileOS
\$0.30 TYMNET
\$31.12 Estimated cost this search
\$31.54 Estimated total session cost 4.386 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 5: Biosis Previews(R) 1969-2000/Apr W1
(c) 2000 BIOSIS
*File 5: Updates renamed. See Help News5.
File 73: EMBASE 1974-2000/Mar W3
(c) 2000 Elsevier Science B.V.
*File 73: New drug links added. See Help News73.
File 155: MEDLINE(R) 1966-2000/May W4
(c) format only 2000 Dialog Corporation
*File 155: MEDLINE will be reloaded. Accession numbers will change.
File 399: CA SEARCH(R) 1967-2000/UD=13214
(c) 2000 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

Set	Items	Description
---	-----	-----
? s	(act(w)1)(30n)	(antibod? or hybridoma?)

Processing
182298 ACT
7136809 1
1522603 ANTIBOD?
42436 HYBRIDOMA?
S1 18 (ACT(W)1)(30N)(ANTIBOD? OR HYBRIDOMA?)
? rd s1

...completed examining records
S2 11 RD S1 (unique items)
? t s2/3/all

2/3/1 (Item 1 from file: 5)
DIALOG(R)File 5: Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

10579258 BIOSIS NO.: 199699200403
Integrin alpha-4-beta-7 mediates human eosinophil interaction with
MAdCAM-1, VCAM-1 and fibronectin.
AUTHOR: Walsh G M(a); Symon F A; Lazarovits A I; Wardlaw A J
AUTHOR ADDRESS: (a)Dep. Respiratory Med., Univ. Leicester Med. Sch.,
Glenfield Hospital, Leicester LE3 9QP**UK
JOURNAL: Immunology 89 (1):p112-119 1996

ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

10579256 BIOSIS NO.: 199699200401
Expression and function of alpha-4/beta-7 integrin on human natural killer cells.
AUTHOR: Perez-Villar J J(a); Zapata J M; Melero I; Postigo A; Sanchez-Madrid F; Lopez-Botet M
AUTHOR ADDRESS: (a)Serv. Immunologia, Hospital de la Princesa, Diego de Leon 62, 28006 Madrid**Spain
JOURNAL: Immunology 89 (1):p96-104 1996
ISSN: 0019-2805
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

08920904 BIOSIS NO.: 199396072405
CD53, a protein with four membrane-spanning domains, mediates signal transduction in human monocytes and B cells.
AUTHOR: Olweus Johanna(a); Lund-Johansen Fridtjof; Horejsi Vaclav
AUTHOR ADDRESS: (a)Res. Dep., Becton Dickinson Immunocytometry Systems, 2350 Qume Drive, San Jose, CA 95131-1807**USA
JOURNAL: Journal of Immunology 151 (2):p707-716 1993
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

06170627 BIOSIS NO.: 000086004809
HUMAN CYTOTROPHOBLASTIC ANTIGENS DEFINED BY MONOCLONAL ANTIBODIES
AUTHOR: ABE Y; OKAMURA K; HAMAZAKI Y; WADA Y; YAJIMA A
AUTHOR ADDRESS: DEP. OBSTET. GYNECOL., TOHOKU UNIV. SCH. MED., SENDAI 980.
JOURNAL: TOHOKU J EXP MED 154 (3). 1988. 245-252.
FULL JOURNAL NAME: Tohoku Journal of Experimental Medicine
CODEN: TJEMA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

2/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

06085943 BIOSIS NO.: 000085049092
IMMUNOPRECIPITATION OF THE INTERLEUKIN 2 RECEPTOR FROM HODGKIN'S DISEASE
DERIVED CELL LINES BY MONOCLONAL ANTIBODIES
AUTHOR: SCHWARTING R; GERDES J; ZIEGLER A; STEIN H
AUTHOR ADDRESS: FREE UNIV. BERLIN, KLINIKUM STEGLITZ, DEP. PATHOL., HINDENBERGDAMM 30, 100 BERLIN 45, WEST GERMANY.

JOURNAL: HEMATOL ONCOL 5 (1). 1987. 57-64.
FULL JOURNAL NAME: Hematological Oncology
CODEN: HAOND
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

2/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

04753088 BIOSIS NO.: 000080056215
ISOLATION AND CHARACTERIZATION OF RAT PLASMA GLANDULAR KALLIKREIN
AUTHOR: MASFERRER J; ALBERTINI R; CROXATTO H R; GARCIA P; PINTO I
AUTHOR ADDRESS: LAB. PHYSIOL., FAC. BIOL. SCI., CATHOLIC UNIV. CHILE,
CASILLA 114-D, SANTIAGO, CHILE.
JOURNAL: BIOCHEM PHARMACOL 34 (1). 1985. 51-56.
FULL JOURNAL NAME: Biochemical Pharmacology
CODEN: BCPCA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

2/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2000 BIOSIS. All rts. reserv.

04552257 BIOSIS NO.: 000029075294
A MONOCLONAL **ANTIBODY** ANTI-ACT-1 DEFINES A NEW LATE
LYMPHOCYTE ACTIVATION ANTIGEN
AUTHOR: LAZAROVITIS A I; MOSCICKI R A; CAMERINI D; KURNICK J T; BHAN A K;
BAIRD L G; ERIKSON M; COSIMI A B; COLVIN R B
AUTHOR ADDRESS: DEP. PATHOL, MASS. GENERAL HOSP., BOSTON, MASS.
JOURNAL: MEETING OF THE CANADIAN SOCIETY OF NEPHROLOGY, MONTREAL, QUE.,
CANADA, SEPT. 10-13, 1984. KIDNEY INT 27 (3). 1985. 594.
CODEN: KDYIA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

2/3/8 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

07235479 EMBASE No: 1998127277
Detection of interleukin-2 receptors on tumor cells in formalin-fixed,
paraffin-embedded tissues
Levi E.; Butmarc J.; Kourea H.P.; Kadin M.E.
Dr. M.E. Kadin, Director of Hematopathology, Beth Israel-Deaconess
Medical Center, Department of Pathology, 330 Brookline Avenue, Boston, MA
02215 United States
Applied Immunohistochemistry (APPL. IMMUNOHISTOCHEM.) (United States)
1997, 5/4 (234-238)
CODEN: APIME ISSN: 1062-3345
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 18

2/3/9 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06796130 EMBASE No: 1997077633
Antigenic determinants of prostate-specific antigen (PSA) and development

of assays specific for different forms of PSA
Nilsson O.; Peter A.; Petersson I.; Nilsson K.; Grundström B.; Karlsson

B.
O. Nilsson, CanAg Diagnostics AB, Majnabbe Terminal Building, SE-414 55
Gothenburg Sweden
British Journal of Cancer (BR. J. CANCER) (United Kingdom) 1997, 75/6
(789-797)
CODEN: BJCAA ISSN: 0007-0920
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 41

2/3/10 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06597695 EMBASE No: 1996262400
Integrin alphainf 4betainf 7 mediates human eosinophil interaction with
MAdCAM-1, VCAM-1 and fibronectin
Walsh G.M.; Symon F.A.; Lazarovits A.I.; Wardlaw A.J.
Department of Respiratory Medicine, University Leicester Medical School,
Glenfield Hospital, Leicester LE3 9QP United Kingdom
Immunology (IMMUNOLOGY) (United Kingdom) 1996, 89/1 (112-119)
CODEN: IMMUA ISSN: 0019-2805
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

2/3/11 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2000 Elsevier Science B.V. All rts. reserv.

06597693 EMBASE No: 1996262398
Expression and function of alphainf 4/betainf 7 integrin on human natural
killer cells
Perez-Villar J.J.; Zapata J.M.; Melero I.; Postigo A.; Sanchez-Madrid F.;
Lopez-Botet M.
Servicio de Inmunologia, Hospital de la Princesa, Diego de Leon 62,28006
Madrid Spain
Immunology (IMMUNOLOGY) (United Kingdom) 1996, 89/1 (96-104)
CODEN: IMMUA ISSN: 0019-2805
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

? t s2/k/all

>>>KWIC option is not available in file(s): 399

2/K/1 (Item 1 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an **antibody** that blocks both alpha-4-beta-1 and alpha-4-beta-7 functions), but not **Act-1**, an alpha-4-beta-7 monoclonal **antibody** (mAb). PAF stimulation resulted in increased binding of eosinophils to MAdCAM-1 transfectants, which was inhibited by both HP1/2 and **Act-1**. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF ...

2/K/2 (Item 2 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: 7 is induced in NK cells upon activation, as the anti-alpha-4-beta-7 **ACT-1** monoclonal **antibody** (mAb) faintly stained a minority of peripheral blood NK cells, whereas it strongly reacted with in vitro long-term interleukin-2 (IL-2)-activated NK cells. Incubation with **ACT-1** or its F(ab')-2 fragments induced a strong homotypic adhesion of NK cells, comparable...

2/K/3 (Item 3 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

MISCELLANEOUS TERMS: ...MONOCLONAL **ANTIBODY ACT-1**;

2/K/4 (Item 4 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

ABSTRACT: Monoclonal **antibodies** have been raised against cytotrophoblast. Two different antigens, defined on cytotrophoblast but not on syncytiotrophoblast were designated **ACT-1** and **ACT-2**, respectively. Chorionic villi were taken from normal early pregnancy and processed for...

2/K/5 (Item 5 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: the interleukin-2 receptor (IL2-R) was detectable on H-RS-cells by three monoclonal **antibodies** (anti-Tac, Tu69 and **ACT-1**) with the sensitive alkaline phosphatase anti-alkaline phosphatase (APAAP) tissue staining procedure. In extension of...

2/K/6 (Item 6 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

...ABSTRACT: ng kinins/min .times. mg) and p-nitroaniline (pNA) from the substrate S-2266 (sp. **act.** 1.23 nmol pNA/min .times. mg); it was inhibited by aprotinin, benzamidine and rat urinary antikallikrein **antibody** but not by ovomucoid. In polyacrylamide gel

electrophoresis, the enzymatic activities of the preparation were...

2/K/7 (Item 7 from file: 5)
DIALOG(R)File 5:(c) 2000 BIOSIS. All rts. reserv.

A MONOCLONAL ANTIBODY ANTI-ACT-1 DEFINES A NEW LATE
LYMPHOCYTE ACTIVATION ANTIGEN

2/K/8 (Item 1 from file: 73)
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

DRUG TERMS (UNCONTROLLED): monoclonal **antibody act 1**

2/K/9 (Item 2 from file: 73)
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...and PSA-ACT. Assays specific for F-PSA (cross-reactivity between F-PSA and PSA-ACT < 1%) were developed by the combination of **antibodies** recognizing epitopes exposed only in F-PSA and **antibodies** recognizing epitopes exposed both in F-PSA and PSA-ACT.

2/K/10 (Item 3 from file: 73)
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...transfectants. Binding of unstimulated eosinophils to VCAM-1 transfectants was inhibited by HP1/2 (an **antibody** that blocks both alpha₄beta₁ and alpha₄beta₇ functions), but not **Act-1**, an alpha₄beta₇ monoclonal **antibody** (mAb). PAF stimulation resulted in increased binding of eosinophils to MADCAM-1 transfectants, which was inhibited by both HP1/2 and **Act-1**. In contrast, PAF did not enhance binding to VCAM-1 transfectants, although binding of PAF...

2/K/11 (Item 4 from file: 73)
DIALOG(R)File 73:(c) 2000 Elsevier Science B.V. All rts. reserv.

...alpha₄beta₇ is induced in NK cells upon activation, as the anti-alpha₄beta₇ **ACT-1** monoclonal **antibody** (mAb) faintly stained a minority of peripheral blood NK cells, whereas it strongly reacted with in vitro long-term interleukin-2 (IL-2)-activated NK cells. Incubation with **ACT-1** or its F(ab')₂ fragments induced a strong homotypic adhesion of NK cells...